FDA Grants Fast Track Designation to Batiraxcept for Kidney Cancer Subset
November 30th 2022The FDA’s decision to grant fast track designation to batiraxcept for treating patients with advanced or metastatic clear cell renal cell carcinoma — a type of kidney cancer — was supported by data from a phase 1b trial.
Daratumumab Combination Demonstrates Efficacy in Relapsed/Refractory Myeloma With EMD
November 30th 2022Among patients with extramedullary multiple myeloma, a regimen consisting of daratumumab plus dexamethasone, cyclophosphamide, etoposide, and cisplatin yielded a complete remission rate of 35.5% and an overall response rate of 67.7%.
Data Support Whole Brain Irradiation Reduction in Pediatric Cancer Survivors
November 28th 2022Results from a pooled case control study indicate that meninges are very radiosensitive in pediatric patients who were treated at prior to age 10 years, supporting reduced dose whole brain irradiation in this population.
Cilta-cel Produces Early Long-Lasting Responses in Pretreated Relapsed/Refractory Multiple Myeloma
November 28th 2022Data from the phase 2 CARTIFAN-1 study highlighted a favorable risk-benefit profile for a single infusion of ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma.
Neeraj Agarwal, MD, Discusses Potential Link Between ctDNA, AR Aberrations, and Survival in mCSPC
November 26th 2022The appearance of circulating tumor DNA and androgen receptor aberrations yielded lower overall survival rates for patients with metastatic castration-sensitive prostate cancer during the phase 3 TITAN trial, according to Agarwal, MD.
Ghassan K. Abou-Alfa, MD, Discusses Next Steps in Researching Unresectable HCC
November 23rd 2022Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
European Commission Approves Cemiplimab for Recurrent/Metastatic Cervical Cancer
November 23rd 2022The European Commission’s approval of cemiplimab for recurrent or metastatic cervical cancer marks the first second-line immunotherapy option available for this patient population regardless of tumor histology.
Belantamab Mafodotin-blmf No Longer Available for Relapsed/Refractory Myeloma in US
November 22nd 2022The FDA recommended that the marketing application for belantamab mafodotin-blmf for patients with previously treated relapsed/refractory multiple myeloma be withdrawn after determining that findings did not meet the requirements for accelerated approval.
Anand Swaminath, MD, Discusses Rationale for Assessing SBRT Vs CRT in Central/Peripheral NSCLC
November 21st 2022Anand Swaminath, MD, reviews the design of the phase 3 LUSTRE trial comparing a 3-week conventional radiotherapy regimen with stereotactic body radiotherapy among patients with stage I medically inoperable non-small cell lung cancer.